Free Alerts   Login
Health Care › Pharmaceutical Preparations

AMPH Stock Price Correlated With Amphastar Pharmaceuticals Financials

AMPH Stock Price vs. Quarterly
AMPH
Income Statement
Cash Flow
Balance Sheet

AMPH Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

AMPH Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

AMPH Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Blackrock.
6,037,158 sh
-53,101 sh
-1%
$373,398
$93,307
Federated Hermes.
3,272,761 sh
-169,473 sh
-5%
$202,420
$44,111
Vanguard Group
2,815,596 sh
48,203 sh
2%
$174,145
$46,873
Neuberger Berman Group
1,693,002 sh
205,023 sh
14%
$104,712
$36,280
State Street
1,471,137 sh
11,646 sh
1%
$90,990
$23,868
Dimensional Fund Advisors
1,339,142 sh
-548,596 sh
-29%
$82,827
-$3,993
Fuller & Thaler Asset Management.
1,273,017 sh
-2,197 sh
0%
$78,736
$20,089
Geode Capital Management
846,652 sh
37,026 sh
5%
$52,371
$15,132
Td Asset Management
793,559 sh
649,001 sh
449%
$49,082
$42,434
Renaissance Technologies
641,900 sh
38,800 sh
6%
$40
$12
Epoch Investment Partners.
592,530 sh
460,473 sh
349%
$36,648
$30,575
Price T Rowe Associates /Md/
586,957 sh
17,245 sh
3%
$36
$10
Northernrp
575,417 sh
15,994 sh
3%
$35,589
$9,861
Morgan Stanley
571,113 sh
12,904 sh
2%
$35,323
$9,650
Invesco.
400,889 sh
-9,740 sh
-2%
$24,795
$5,910
BOONE CAPITAL MANAGEMENT
400,000 sh
400,000 sh
NEW
$24,740
$24,740
Charles Schwab Investment Management
379,480 sh
27,102 sh
8%
$23,471
$7,265
Granite Investment Partners
365,340 sh
34,429 sh
10%
$22,596
$7,377
Oberweis Asset Management/
340,265 sh
187,765 sh
123%
$21,045
$14,032
American Century Companies
337,690 sh
337,690 sh
NEW
$20,886
$20,886
COMPANY PROFILE
Note 1. Genera l ​ Amphastar Pharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, hereinafter referred to as the “Company”) is a bio-pharmaceutical company that develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products, including products with high technical barriers to market entry. Additionally, the Company sells insulin active pharmaceutical ingredient, or API, products. Most of the Company’s products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company’s insulin API products are sold to other pharmaceutical companies for use in their own products and are being used by the Company in the development of injectable finished pharmaceutical products. The Company’s inhalation product, Primatene Mist ®, is primarily distributed through drug retailers. ​ The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2021 and the notes thereto as filed with the Securities and Exchange Commission, or SEC, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with United States generally accepted accounting principles, or GAAP, have been condensed or omitted from the accompanying condensed consolidated financial statements. The accompanying year-end condensed consolidated balance sheet was derived from the audited financial statements. The accompanying interim financial statements are unaudited, but reflect all adjustments which are, in the opinion of management, necessary for a fair statement of the Company’s consolidated financial position, results of operations, comprehensive income (loss), stockholders’ equity, and cash flows for the periods presented. Unless otherwise noted, all such adjustments are of a normal, recurring nature. The Company’s results of operations, comprehensive income (loss) and cash flows for the interim periods are not necessarily indicative of the results of operations and cash flows that it may achieve in future periods.

Free historical financial statements for Amphastar Pharmaceuticals Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 36 quarters since 2015. Compare with AMPH stock chart to see long term trends.

Data imported from Amphastar Pharmaceuticals Inc SEC filings. Check original filings before making any investment decision.